The Cancer-Immunity Cycle in Multiple Myeloma

References

• van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427. doi:10.1016/S0140-6736(21)00135-5
   PubMed Web of Science ®Google Scholar
• Ledergor G, Weiner A, Zada M, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24(12):1867–1876. doi:10.1038/s41591-018-0269-2
   PubMed Web of Science ®Google Scholar
• Rustad EH, Yellapantula V, Leongamornlert D, et al. Timing the initiation of multiple myeloma. Nat Commun. 2020;11(1):1917. doi:10.1038/s41467-020-15740-9
   Web of Science ®Google Scholar
• van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78(10):2449–2456. doi:10.1158/0008-5472.CAN-17-3115
   Web of Science ®Google Scholar
• Schürch CM, Rasche L, Frauenfeld L, Weinhold N, Fend F. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. Virchows Arch. 2020;476(3):337–351. doi:10.1007/s00428-019-02725-3
   PubMed Web of Science ®Google Scholar
• Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood. 2020;136(24):2731–2740. doi:10.1182/blood.2020006540
   PubMed Web of Science ®Google Scholar
• Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130(4):1565–1575. doi:10.1172/JCI129205
   PubMed Web of Science ®Google Scholar
• Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and targeted approaches in multiple myeloma. Immunotargets Ther. 2020;9:201–215. doi:10.2147/ITT.S240886
   Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ. Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin Dev Immunol. 2012;2012:397648. doi:10.1155/2012/397648
   PubMedGoogle Scholar
• Hoang MD, Jung SH, Lee HJ, et al. Dendritic cell-based cancer immunotherapy against multiple myeloma: from bench to clinic. Chonnam Med J. 2015;51(1):1–7. doi:10.4068/cmj.2015.51.1.1
   Google Scholar
• Blotta S, Tassone P, Prabhala RH, et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009;114(15):3276–3284. doi:10.1182/blood-2009-04-219436
   Web of Science ®Google Scholar
• Dhodapkar MV, Sexton R, Das R, et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood. 2015;126(22):2475–2478. doi:10.1182/blood-2015-03-632919
   PubMed Web of Science ®Google Scholar
• Jiang T, Shi T, Zhang H, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12(1):93. doi:10.1186/s13045-019-0787-5
   PubMed Web of Science ®Google Scholar
• Miller A, Asmann Y, Cattaneo L, et al. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood Cancer J. 2017;7(9):e612. doi:10.1038/bcj.2017.94
   PubMed Web of Science ®Google Scholar
• Perumal D, Imai N, Lagana A, et al. Mutation-derived neoantigen-specific T-cell responses in multiple myeloma. Clin Cancer Res. 2020;26(2):450–464. doi:10.1158/1078-0432.CCR-19-2309
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Schjesvold F, Oriol A, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, Phase 3 trial. Lancet Haematol. 2019;6(9):e448–e458. doi:10.1016/S2352-3026(19)30109-7
   PubMed Web of Science ®Google Scholar
• Mateos MV, Blacklock H, Schjesvold F, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6(9):e459–e469. doi:10.1016/S2352-3026(19)30110-3
   PubMed Web of Science ®Google Scholar
• Roberts EW, Broz ML, Binnewies M, et al. Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30(2):324–336. doi:10.1016/j.ccell.2016.06.003
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Garbi N, et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med. 2003;9(9):1151–1157. doi:10.1038/nm914
   PubMed Web of Science ®Google Scholar
• Cavanagh LL, Bonasio R, Mazo IB, et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat Immunol. 2005;6(10):1029–1037. doi:10.1038/ni1249
   PubMed Web of Science ®Google Scholar
• Asano K, Nabeyama A, Miyake Y, et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity. 2011;34(1):85–95. doi:10.1016/j.immuni.2010.12.011
   PubMed Web of Science ®Google Scholar
• Chesi M, Mirza NN, Garbitt VM, et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016;22(12):1411–1420. doi:10.1038/nm.4229
   PubMed Web of Science ®Google Scholar
• Guillerey C, Nakamura K, Vuckovic S, Hill GR, Smyth MJ. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci. 2016;73(8):1569–1589. doi:10.1007/s00018-016-2135-z
   PubMed Web of Science ®Google Scholar
• Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604. doi:10.1146/annurev-immunol-020711-074950
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003;198(11):1753–1757. doi:10.1084/jem.20031030
   PubMed Web of Science ®Google Scholar
• Bailur JK, McCachren SS, Doxie DB, et al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight. 2019;5:e127807. doi:10.1172/jci.insight.127807
   Web of Science ®Google Scholar
• Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1(5):493–506. doi:10.1038/s43018-020-0053-3
   PubMedGoogle Scholar
• Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clin Cancer Res. 2020;26(7):1541–1554. doi:10.1158/1078-0432.CCR-19-2111
   PubMed Web of Science ®Google Scholar
• Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2021. doi:10.1038/s41417-021-00303-x
   PubMed Web of Science ®Google Scholar
• Chow MT, Ozga AJ, Servis RL, et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity. 2019;50(6):1498–1512.e1495. doi:10.1016/j.immuni.2019.04.010
   PubMed Web of Science ®Google Scholar
• Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol. 2005;26(7):360–366. doi:10.1016/j.it.2005.04.011
   PubMed Web of Science ®Google Scholar
• Ponzetta A, Benigni G, Antonangeli F, et al. Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. Cancer Res. 2015;75(22):4766–4777. doi:10.1158/0008-5472.CAN-15-1320
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Mishima Y, Sacco A, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 2015;12(4):622–635. doi:10.1016/j.celrep.2015.06.059
   PubMed Web of Science ®Google Scholar
• Vandyke K, Zeissig MN, Hewett DR, et al. HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Res. 2017;77(20):5452–5463. doi:10.1158/0008-5472.CAN-17-0115
   Web of Science ®Google Scholar
• Mushtaq MU, Papadas A, Pagenkopf A, et al. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. J Immunother Cancer. 2018;6(1):65. doi:10.1186/s40425-018-0376-0
   PubMed Web of Science ®Google Scholar
• Hope C, Ollar SJ, Heninger E, et al. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014;123(21):3305–3315. doi:10.1182/blood-2014-02-554071
   PubMed Web of Science ®Google Scholar
• Dhakal B, Pagenkopf A, Mushtaq MU, et al. Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma. 2019;60(10):2558–2562. doi:10.1080/10428194.2019.1585836
   PubMed Web of Science ®Google Scholar
• Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34(1):1–20. doi:10.1038/s41375-019-0660-0
   PubMed Web of Science ®Google Scholar
• Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127(8):971–976. doi:10.1182/blood-2015-07-635383
   PubMed Web of Science ®Google Scholar
• Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543–9551. doi:10.1073/pnas.1819745116
   PubMed Web of Science ®Google Scholar
• Firsova MV, Mendeleeva LP, Kovrigina AM, Solovev MV, Savchenko VG. Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry. BMC Cancer. 2020;20(1):346. doi:10.1186/s12885-020-06870-w
   Web of Science ®Google Scholar
• Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13(1):54. doi:10.1186/s13045-020-00890-6
   PubMed Web of Science ®Google Scholar
• Dieckmann NM, Frazer GL, Asano Y, Stinchcombe JC, Griffiths GM. The cytotoxic T lymphocyte immune synapse at a glance. J Cell Sci. 2016;129(15):2881–2886. doi:10.1242/jcs.186205
   Web of Science ®Google Scholar
• Shi J, Tricot GJ, Garg TK, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008;111(3):1309–1317. doi:10.1182/blood-2007-03-078535
   PubMed Web of Science ®Google Scholar
• Kowalewski DJ, Walz S, Backert L, et al. Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. Blood Cancer J. 2016;6(4):e411. doi:10.1038/bcj.2016.14
   Web of Science ®Google Scholar
• Salik B, Smyth MJ, Nakamura K. Targeting immune checkpoints in hematological malignancies. J Hematol Oncol. 2020;13(1):111. doi:10.1186/s13045-020-00947-6
   PubMed Web of Science ®Google Scholar
• Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;130(10):1189–1197. doi:10.1182/blood-2017-03-775122
   PubMed Web of Science ®Google Scholar
• Kwon M, Kim CG, Lee H, et al. PD-1 blockade reinvigorates bone marrow CD8(+) T cells from patients with multiple myeloma in the presence of TGFβ inhibitors. Clin Cancer Res. 2020;26(7):1644–1655. doi:10.1158/1078-0432.CCR-19-0267
   PubMed Web of Science ®Google Scholar
• Guillerey C, Ferrari de Andrade L, Vuckovic S, et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest. 2015;125(5):2077–2089. doi:10.1172/JCI77181
   Web of Science ®Google Scholar
• Weulersse M, Asrir A, Pichler AC, et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8(+) T cell anti-tumor functions and limits the efficacy of cancer immunotherapy. Immunity. 2020;53(4):824–839.e810. doi:10.1016/j.immuni.2020.09.006
   Web of Science ®Google Scholar
• Braun M, Aguilera AR, Sundarrajan A, et al. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells. Immunity. 2020;53(4):805–823.e815. doi:10.1016/j.immuni.2020.09.010
   PubMed Web of Science ®Google Scholar
• Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38(1):20–28. doi:10.1016/j.it.2016.10.002
   PubMed Web of Science ®Google Scholar
• Guillerey C, Harjunpaa H, Carrie N, et al. TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood. 2018;132(16):1689–1694. doi:10.1182/blood-2018-01-825265
   PubMed Web of Science ®Google Scholar
• Minnie SA, Kuns RD, Gartlan KH, et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood. 2018;132(16):1675–1688. doi:10.1182/blood-2018-01-825240
   PubMed Web of Science ®Google Scholar
• Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21(8):835–847. doi:10.1038/s41590-020-0728-z
   PubMed Web of Science ®Google Scholar
• Barberi C, De Pasquale C, Allegra A, et al. Myeloma cells induce the accumulation of activated CD94 low NK cells by cell-to-cell contacts involving CD56 molecules. Blood Adv. 2020;4(10):2297–2307. doi:10.1182/bloodadvances.2019000953
   Web of Science ®Google Scholar
• Kini Bailur J, Mehta S, Zhang L, et al. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Adv. 2017;1(25):2343–2347. doi:10.1182/bloodadvances.2017012732
   Web of Science ®Google Scholar
• Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med. 2003;197(12):1667–1676. doi:10.1084/jem.20021650
   PubMed Web of Science ®Google Scholar
• Nakamura K, Smyth MJ. Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol. 2017;95(4):325–332. doi:10.1038/icb.2016.126
   PubMed Web of Science ®Google Scholar
• Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):1–12. doi:10.1038/s41423-019-0306-1
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kassem S, Cleynen A, et al. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018;33(4):634–648.e635. doi:10.1016/j.ccell.2018.02.007
   PubMed Web of Science ®Google Scholar
• Perez C, Botta C, Zabaleta A, et al. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020;136(2):199–209. doi:10.1182/blood.2019004537
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086. doi:10.1158/2159-8290.CD-18-0367
   PubMed Web of Science ®Google Scholar
• Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356–371. doi:10.1038/s41571-019-0175-7
   PubMed Web of Science ®Google Scholar
• Kamada T, Togashi Y, Tay C, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116(20):9999–10008. doi:10.1073/pnas.1822001116
   PubMed Web of Science ®Google Scholar
• Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21(11):1346–1358. doi:10.1038/s41590-020-0769-3
   PubMed Web of Science ®Google Scholar
• Zhao E, Wang L, Dai J, et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology. 2012;1(2):152–161. doi:10.4161/onci.1.2.18480
   PubMed Web of Science ®Google Scholar
• Glatman Zaretsky A, Konradt C, Depis F, et al. T regulatory cells support plasma cell populations in the bone marrow. Cell Rep. 2017;18(8):1906–1916. doi:10.1016/j.celrep.2017.01.067
   Web of Science ®Google Scholar
• Kawano Y, Zavidij O, Park J, et al. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018;128(6):2487–2499. doi:10.1172/JCI88169
   Web of Science ®Google Scholar
• Zhang L, Tai YT, Ho M, et al. Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu. Blood Cancer J. 2017;7(3):e547. doi:10.1038/bcj.2017.24
   Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. doi:10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Gulla A, Morelli E, Samur MK, et al. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021. doi:10.1158/2643-3230.BCD-21-0047
   Google Scholar
• Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–3138. doi:10.1182/blood-2013-10-535088
   PubMed Web of Science ®Google Scholar
• Richardson PG, Lee HC, Abdallah AO, et al. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J. 2020;10(10):106. doi:10.1038/s41408-020-00369-0
   PubMed Web of Science ®Google Scholar
• Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer. 2018;6(1):46. doi:10.1186/s40425-018-0361-7
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Dew A, Hill E, et al. Avelumab, a PD-L1 inhibitor, in combination with hypofractionated radiotherapy and the abscopal effect in relapsed refractory multiple myeloma. Oncologist. 2021;26(4):288–e541. doi:10.1002/onco.13712
   Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711–1721. doi:10.1056/NEJMoa1807315
   PubMed Web of Science ®Google Scholar
• Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209–1215. doi:10.1038/nm.3931
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22–32. doi:10.1038/leu.2009.236
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164(6):811–821. doi:10.1111/bjh.12708
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210–216. doi:10.1182/blood.V98.1.210
   PubMed Web of Science ®Google Scholar
• Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015;126(1):50–60. doi:10.1182/blood-2015-01-625004
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811–1822. doi:10.1056/NEJMoa1805762
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91. doi:10.1038/s41408-020-00357-4
   PubMed Web of Science ®Google Scholar
• Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res. 2018;24(1):106–119. doi:10.1158/1078-0432.CCR-17-0344
   PubMed Web of Science ®Google Scholar
• Kuwahara-Ota S, Shimura Y, Steinebach C, et al. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma. Br J Haematol. 2020;191(5):784–795. doi:10.1111/bjh.16881
   Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58(7):1033–1045. doi:10.1007/s00262-008-0620-4
   PubMed Web of Science ®Google Scholar
• Minnie SA, Hill GR. Autologous stem cell transplantation for myeloma: cytoreduction or an Immunotherapy? Front Immunol. 2021;12:651288. doi:10.3389/fimmu.2021.651288
   Web of Science ®Google Scholar
• Vuckovic S, Minnie SA, Smith D, et al. Bone marrow transplantation generates T cell-dependent control of myeloma in mice. J Clin Invest. 2019;129(1):106–121. doi:10.1172/JCI98888
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Villasboas JC, Jessen E, et al. Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. Blood Cancer J. 2019;9(9):72. doi:10.1038/s41408-019-0234-4
   PubMed Web of Science ®Google Scholar
• Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4(1):61–71. doi:10.1158/2326-6066.CIR-15-0055
   PubMed Web of Science ®Google Scholar
• Lee L, Alrasheed N, Khandelwal G, et al. Increased immune-regulatory receptor expression on effector T cells as early indicators of relapse following autologous stem cell transplantation for multiple myeloma. Front Immunol. 2021;12:618610. doi:10.3389/fimmu.2021.618610
   Web of Science ®Google Scholar
• Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies. JCO Oncol Pract. 2020;16(2):56–66. doi:10.1200/JOP.19.00335
   PubMedGoogle Scholar
• Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol. 2018;9:2722. doi:10.3389/fimmu.2018.02722
   PubMed Web of Science ®Google Scholar
• Hashmi H, Husnain M, Khan A, Usmani SZ. CD38-directed therapies for management of multiple myeloma. Immunotargets Ther. 2021;10:201–211. doi:10.2147/ITT.S259122
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394. doi:10.1182/blood-2015-12-687749
   PubMed Web of Science ®Google Scholar
• Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20(17):4574–4583. doi:10.1158/1078-0432.CCR-14-0695
   PubMed Web of Science ®Google Scholar
• Nakamura K, Casey M, Oey H, et al. Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia. 2020;34(10):2708–2721. doi:10.1038/s41375-020-0811-3
   PubMed Web of Science ®Google Scholar
• Adams HC 3rd, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A. 2019;95(3):279–289. doi:10.1002/cyto.a.23693
   PubMed Web of Science ®Google Scholar
• Lucas F, Pennell M, Huang Y, et al. T cell transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma. Biol Blood Marrow Transplant. 2020;26(1):7–15. doi:10.1016/j.bbmt.2019.08.009
   Web of Science ®Google Scholar
• Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like Protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176(1–2):334–347.e312. doi:10.1016/j.cell.2018.11.010
   PubMed Web of Science ®Google Scholar
• Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):125. doi:10.1186/s13045-020-00962-7
   Web of Science ®Google Scholar
• Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi:10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Samur MK, Fulciniti M, Aktas samur A, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868. doi:10.1038/s41467-021-21177-5
   PubMed Web of Science ®Google Scholar
• Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267–2280. doi:10.1200/JCO.2018.77.8084
   PubMed Web of Science ®Google Scholar
• Ahn S, Leblay N, Neri P. Understanding the mechanisms of resistance to T cell-based immunotherapies to develop more favorable strategies in multiple myeloma. Hemasphere. 2021;5(6):e575. doi:10.1097/HS9.0000000000000575
   PubMed Web of Science ®Google Scholar
• Hosen N, Matsunaga Y, Hasegawa K, et al. The activated conformation of integrin β(7) is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med. 2017;23(12):1436–1443. doi:10.1038/nm.4431
   Web of Science ®Google Scholar
• Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746. doi:10.1126/scitranslmed.aau7746
   PubMed Web of Science ®Google Scholar
• Lee L, Draper B, Chaplin N, et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood. 2018;131(7):746–758. doi:10.1182/blood-2017-05-781351
   PubMed Web of Science ®Google Scholar
• Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, Phase 2 trial. Lancet Haematol. 2019;6(10):e521–e529. doi:10.1016/S2352-3026(19)30115-2
   PubMed Web of Science ®Google Scholar
• D’Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2020;34(1):21–34. doi:10.1038/s41375-019-0669-4
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–553. doi:10.1056/NEJMoa1910607
   PubMed Web of Science ®Google Scholar